CD8A and neoplasm: Additional research suggested that T-cell clones shared between blood and tumor (overlapping clones) are those more informative on the clinical outcome, as a higher frequency of overlapping clones within peripheral CD8+ T cells before anti-PD-1 treatment was associated with a favorable clinical response [106–108].